Roche’s Divarasib Shows Competitive Data As Monotherapy In KRAS

 
• By Joseph Haas
  
KRAS G12C protein
Roche is working to compete with Amgen, Mirati in KRAS inhibition • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D